KACST, Pfizer Sign MoU to Develop Vaccines and Gene Therapies

Thursday 1444/5/7 - 2022/12/01
  • Share on Google+

Riyadh, December 01, 2022, SPA -- King Abdulaziz City for Science and Technology (KACST) and the Saudi Pfizer Company signed a memorandum of understanding (MoU) to develop vaccines and genetic treatments to combat genetic diseases, represented by the Vice President of the Health Sector, Dr. Batoul Baz, and the CEO of the company’s medical department, Hani Al-Hashmi.
The signing of the MoU was attended by KACST President Dr. Mounir bin Mahmoud Al-Desouki, and the President of Pfizer Emerging Markets, Nick Lagunowich.
The cooperation aims to meet the aspirations of national priorities for the research, development, and innovation sector through the development of vaccines and gene therapies, advisory support for the Saudi Genome Program in its second phase, and the investigation of scientific and research partnerships in the local and global markets.
The MoU includes research cooperation in genetic diseases, research on aging, infections, immune diseases, cancers, and chronic diseases, in addition to hosting Pfizer factories for KACST researchers and exchanging scientific knowledge.
19:00 LOCAL TIME 16:00 GMT